Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation

Anna Locasciulli, Andrea Bacigalupo, Alfredo Alberti, Maria Teresa Van Lint, Cornelio Uderzo, Alberto M. Marmont, Howard M. Shulman, Bernard Portmann

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

This study was undertaken to evaluate the occurrence of VOD and other liver diseases following BMT in a patient population with a high incidence of hepatitis before conditioning regimen. We prospectively reviewed 186 consecutive patients undergoing BMT from 1976 to 1986 to determine incidence and type of liver disease after BMT and predisposing factors. Two of 186 patients experienced VOD (1.07%). Acute and chronic liver GVHD were found in 25.8% and 36% of the patients, respectively. Acute hepatitis (AH) was diagnosed in 29.4% and chronic hepatitis (CH) in 42.6% of the patients. Statistical analysis showed no influence of pretransplant variables on the occurrence of acute GVHD and AH; there was a weak correlation (P=0.01) between pre-BMT abnormal transaminases and occurrence of chronic GVHD. Contingency table and Cox analysis showed a greater risk of CH for patients with abnormal pretransplant SGPT levels (P=0.0004 and P=0.0022). No other variables could be associated with posttransplant CH. Actuarial survival was 71% versus 69% for patients with normal versus abnormal transaminases (P=0.2). As VOD was a rare event, despite 63% of patients having abnormal transaminase values before transplant, we suggest that a lower and slower TBI is more important than pretransplant normal transaminases in preventing this complication. We conclude that evidence of compensated hepatitis is not a relative contraindication for BMT.

Original languageEnglish
Pages (from-to)68-71
Number of pages4
JournalTransplantation
Volume48
Issue number1
Publication statusPublished - 1989

Fingerprint

Homologous Transplantation
Bone Marrow Transplantation
Transplants
Liver
Transaminases
Hepatitis
Chronic Hepatitis
Liver Diseases
Incidence
Alanine Transaminase
Causality
Survival
Population

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Locasciulli, A., Bacigalupo, A., Alberti, A., Teresa Van Lint, M., Uderzo, C., Marmont, A. M., ... Portmann, B. (1989). Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. Transplantation, 48(1), 68-71.

Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. / Locasciulli, Anna; Bacigalupo, Andrea; Alberti, Alfredo; Teresa Van Lint, Maria; Uderzo, Cornelio; Marmont, Alberto M.; Shulman, Howard M.; Portmann, Bernard.

In: Transplantation, Vol. 48, No. 1, 1989, p. 68-71.

Research output: Contribution to journalArticle

Locasciulli, A, Bacigalupo, A, Alberti, A, Teresa Van Lint, M, Uderzo, C, Marmont, AM, Shulman, HM & Portmann, B 1989, 'Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation', Transplantation, vol. 48, no. 1, pp. 68-71.
Locasciulli, Anna ; Bacigalupo, Andrea ; Alberti, Alfredo ; Teresa Van Lint, Maria ; Uderzo, Cornelio ; Marmont, Alberto M. ; Shulman, Howard M. ; Portmann, Bernard. / Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation. In: Transplantation. 1989 ; Vol. 48, No. 1. pp. 68-71.
@article{284dc68072d3411584b31277cb2d5cce,
title = "Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation",
abstract = "This study was undertaken to evaluate the occurrence of VOD and other liver diseases following BMT in a patient population with a high incidence of hepatitis before conditioning regimen. We prospectively reviewed 186 consecutive patients undergoing BMT from 1976 to 1986 to determine incidence and type of liver disease after BMT and predisposing factors. Two of 186 patients experienced VOD (1.07{\%}). Acute and chronic liver GVHD were found in 25.8{\%} and 36{\%} of the patients, respectively. Acute hepatitis (AH) was diagnosed in 29.4{\%} and chronic hepatitis (CH) in 42.6{\%} of the patients. Statistical analysis showed no influence of pretransplant variables on the occurrence of acute GVHD and AH; there was a weak correlation (P=0.01) between pre-BMT abnormal transaminases and occurrence of chronic GVHD. Contingency table and Cox analysis showed a greater risk of CH for patients with abnormal pretransplant SGPT levels (P=0.0004 and P=0.0022). No other variables could be associated with posttransplant CH. Actuarial survival was 71{\%} versus 69{\%} for patients with normal versus abnormal transaminases (P=0.2). As VOD was a rare event, despite 63{\%} of patients having abnormal transaminase values before transplant, we suggest that a lower and slower TBI is more important than pretransplant normal transaminases in preventing this complication. We conclude that evidence of compensated hepatitis is not a relative contraindication for BMT.",
author = "Anna Locasciulli and Andrea Bacigalupo and Alfredo Alberti and {Teresa Van Lint}, Maria and Cornelio Uderzo and Marmont, {Alberto M.} and Shulman, {Howard M.} and Bernard Portmann",
year = "1989",
language = "English",
volume = "48",
pages = "68--71",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Predictability before transplant of hepatic complications following allogeneic bone marrow transplantation

AU - Locasciulli, Anna

AU - Bacigalupo, Andrea

AU - Alberti, Alfredo

AU - Teresa Van Lint, Maria

AU - Uderzo, Cornelio

AU - Marmont, Alberto M.

AU - Shulman, Howard M.

AU - Portmann, Bernard

PY - 1989

Y1 - 1989

N2 - This study was undertaken to evaluate the occurrence of VOD and other liver diseases following BMT in a patient population with a high incidence of hepatitis before conditioning regimen. We prospectively reviewed 186 consecutive patients undergoing BMT from 1976 to 1986 to determine incidence and type of liver disease after BMT and predisposing factors. Two of 186 patients experienced VOD (1.07%). Acute and chronic liver GVHD were found in 25.8% and 36% of the patients, respectively. Acute hepatitis (AH) was diagnosed in 29.4% and chronic hepatitis (CH) in 42.6% of the patients. Statistical analysis showed no influence of pretransplant variables on the occurrence of acute GVHD and AH; there was a weak correlation (P=0.01) between pre-BMT abnormal transaminases and occurrence of chronic GVHD. Contingency table and Cox analysis showed a greater risk of CH for patients with abnormal pretransplant SGPT levels (P=0.0004 and P=0.0022). No other variables could be associated with posttransplant CH. Actuarial survival was 71% versus 69% for patients with normal versus abnormal transaminases (P=0.2). As VOD was a rare event, despite 63% of patients having abnormal transaminase values before transplant, we suggest that a lower and slower TBI is more important than pretransplant normal transaminases in preventing this complication. We conclude that evidence of compensated hepatitis is not a relative contraindication for BMT.

AB - This study was undertaken to evaluate the occurrence of VOD and other liver diseases following BMT in a patient population with a high incidence of hepatitis before conditioning regimen. We prospectively reviewed 186 consecutive patients undergoing BMT from 1976 to 1986 to determine incidence and type of liver disease after BMT and predisposing factors. Two of 186 patients experienced VOD (1.07%). Acute and chronic liver GVHD were found in 25.8% and 36% of the patients, respectively. Acute hepatitis (AH) was diagnosed in 29.4% and chronic hepatitis (CH) in 42.6% of the patients. Statistical analysis showed no influence of pretransplant variables on the occurrence of acute GVHD and AH; there was a weak correlation (P=0.01) between pre-BMT abnormal transaminases and occurrence of chronic GVHD. Contingency table and Cox analysis showed a greater risk of CH for patients with abnormal pretransplant SGPT levels (P=0.0004 and P=0.0022). No other variables could be associated with posttransplant CH. Actuarial survival was 71% versus 69% for patients with normal versus abnormal transaminases (P=0.2). As VOD was a rare event, despite 63% of patients having abnormal transaminase values before transplant, we suggest that a lower and slower TBI is more important than pretransplant normal transaminases in preventing this complication. We conclude that evidence of compensated hepatitis is not a relative contraindication for BMT.

UR - http://www.scopus.com/inward/record.url?scp=0024330180&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024330180&partnerID=8YFLogxK

M3 - Article

VL - 48

SP - 68

EP - 71

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 1

ER -